Abstract
A wide variety of up-to-date results and knowledge were presented at the 10th International AIDS Meeting, Yokohama. Epidemiologically, most interest was focused on the discovery of a new HIV subtype O, which cannot be reliably detected by currently available ELISA kits. Clinically, it is gradually appreciated that one single most important parameter is the viral load; the extent of viral load can help explain many clinical observations. Another eye-catching finding was the report of a clinical follow-up of a group of long-term nonprogressors. If the underlying operative mechanism can be elucidated, we can learn the necessary elements for halting HIV infection progression. Therapeutically, the trend has shifted to combination therapy, preferentially 3-drug combination of 2 RT inhibitors and 1 protease inhibitor. For the vaccine development, many novel vectors were introduced, but their potentials are unknown at present. The successful application of single-cell in situ PCR has changed our perception of HIV infection. This powerful technique can detect a single viral genome inside cells and revealed that a large proportion of cells already harbor HIV genomes soon after the entry of HIV into the body. A direct viral effect may fully explain subsequent T cell depletion without invoking a lot of indirect mechanisms such as apoptosis.
Article PDF
Avoid common mistakes on your manuscript.
References
De Leys R, Vanderborght B, van den Haesevelde M, et al. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of west-central African origin. J Virol 64:1207–1216;1990.
Haynes BF. Scientific and social issues of human immunodeficiency virus vaccine development. Science 260:1279–1286;1993.
Letvin NL. Vaccines against human immunodeficiency virus — progress and prospects. N Engl J Med 329:1400–1405;1993.
Liu MA, Vogel FR. Use of novel DNA vectors and immunologic adjuvants in HIV vaccine development. AIDS 8(suppl 1):S195-S201;1984.
McMichael AJ, Walker BD. Cytotoxic T lymphocyte epitopes. Implication for HIV vaccine. AIDS 8(suppl):S155-S173;1994.
Myers G, Korber B, Berzofsky JA, Smith RF, Pavlakis GN (eds). Human Retroviruses and AIDS; a Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 1993.
Schultz AM, Stott EJ. Primate models for AIDS vaccines. AIDS 8(suppl 1):S213-S236;1994.
Tsubota H, Lord CI, Watkins DI, Morimoto C, Letvin NL. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 169:1421–1434;1987.
Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563–1566;1986.
Walker MC, Fast PE. Clinical trials of candidate AIDS vaccines. AIDS 8(suppl 1):S213-S236;1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chang, LJ., Chen, YM.A., Chen, MY. et al. HIV 10 years later-where do we stand now?. J Biomed Sci 2, 1–11 (1995). https://doi.org/10.1007/BF02257919
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02257919